| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 138: 46-50 (1981)
© 1981 The Royal College of Psychiatrists
JE Christie, A Shering, J Ferguson and AI Glen
Physostigmine (0.25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia. Significant improvement was seen on a picture recognition test with physostigmine 0.375 mg and arecholine 4 mg. A trend towards improvement was also seen with physostigmine 0.25 mg and 0.75 mg, and arecholine 2 mg. For the majority of the patients improvement was only slight but in two patients it was clear cut and consistent.
This article has been cited by other articles:
|
|
 |
|
  P. Bentley, J. Driver, and R. J. Dolan Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health Brain, February 1, 2008; 131(2): 409 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Thal, M. Forrest, H. Loft, and H. Mengel Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease Neurology, January 25, 2000; 54(2): 421 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Schwarz, M. J. Callahan, L. L. Coughenour, M. R. Dickerson, J. J. Kinsora, W. J. Lipinski, C. A. Raby, C. J. Spencer, and H. Tecle Milameline (CI-979/RU35926): A Muscarinic Receptor Agonist with Cognition-Activating Properties: Biochemical and In Vivo Characterization J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 812 - 822. [Abstract] [Full Text]
|
|
|
|
 |
|
 N.H.P. Allen and A. Burns The treatment of Alzheimer's disease J Psychopharmacol, January 1, 1995; 9(1): 43 - 56. [PDF]
|
|
|
|
 |
|
 B. E McGuire Review article : Psychopharmacological treatments for memory impairment Clinical Rehabilitation, August 1, 1990; 4(3): 235 - 244. [PDF]
|
|
|
|
 |
|
 Notices J Geriatr Psychiatry Neurol, April 1, 1990; 3(2): 119 - 120. [PDF]
|
|
|
|
|
|
G.C. Preston, C. Brazell, C. Ward, P. Broks, M. Traub, and S.M. Stahl The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man J Psychopharmacol, January 1, 1988; 2(2): 67 - 79. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Arnsten and P. Goldman-Rakic Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates Science, December 13, 1985; 230(4731): 1273 - 1276. [Abstract] [PDF]
|
|
|
|
|
|
J. Coyle, D. Price, and M. DeLong Alzheimer's disease: a disorder of cortical cholinergic innervation Science, March 11, 1983; 219(4589): 1184 - 1190. [Abstract] [PDF]
|
|
|
|
|
|
R. Bartus, R. Dean 3rd, B Beer, and A. Lippa The cholinergic hypothesis of geriatric memory dysfunction Science, July 30, 1982; 217(4558): 408 - 414. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
